Requests that the FDA take the following actions: 1. Decline to accept or approve any ANDA or section 505(b)(2) application referencing or relying upon ACETADOTE with labeling that omits the information in ACETADOTE’s prescribing information relating to a two-bag dosing regimen and the associated reduction in risk of hypersensitivity reactions